Oct 24, 2024 | Press Releases
Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors First natural killer cell-based cellular therapy study conducted in the continent of Africa Complete enrollment currently expected in Q1 2025 CULVER CITY, Calif.,...
Oct 21, 2024 | Press Releases
CULVER CITY, Calif., October 21, 2024 — Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London Healthcare Conference, which is taking place November 19-21 at the Waldorf Hilton...
Sep 9, 2024 | Press Releases
Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2nd and 3rd line NSCLC cancer patients who progressed on checkpoint inhibitors such as KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab)...
Aug 12, 2024 | Press Releases
ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval Global expansion of commercial and clinical bladder cancer programs Filing process initiated with European Medicines Agency (EMA) for regulatory approval of...
Aug 6, 2024 | Press Releases
The QUILT 502 trial is testing ImmunityBio’s N-803 (ANKTIVA®) in combination with the AdHER2DC investigational vaccine for endometrial cancer, a gynecological cancer with lower survival rates and limited effective post-second-line treatment. The AdHER2DC vaccine...
Jun 20, 2024 | Press Releases
Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer ANKTIVA launch initiates the next era of immunotherapy beyond checkpoint...